{
    "clinical_study": {
        "@rank": "51824", 
        "acronym": "Statin DDI", 
        "arm_group": [
            {
                "arm_group_label": "Rosuvastatin", 
                "arm_group_type": "Experimental", 
                "description": "Single, oral dose of rosuvastatin 20mg in first period and in second period (after wash out) fostamatinib 100 mg twice daily, then single oral dose of rosuvastatin 20 mg plus continued oral dosing of fostamatinib 100 mg twice daily, then continue fostamatinib 100 mg twice daily"
            }, 
            {
                "arm_group_label": "Simvastatin", 
                "arm_group_type": "Experimental", 
                "description": "Single, oral dose of simvastatin 40 mg in first period and in second period (after wash out) fostamatinib 100 mg twice daily, then single oral dose of simvastatin 40 mg plus continued oral dosing of fostamatinib 100 mg twice daily, then continue fostamatinib 100 mg twice daily"
            }
        ], 
        "brief_summary": {
            "textblock": "A study to Assess the Pharmacokinetics of Rosuvastatin and Simvastatin when administered\n      alone or in combination with Fostamatinib."
        }, 
        "brief_title": "Assess the Pharmacokinetics of Rosuvastatin and Simvastatin When Administered Alone or in Combination With Fostamatinib", 
        "completion_date": {
            "#text": "January 2013", 
            "@type": "Actual"
        }, 
        "condition": "Rheumatoid Arthritis", 
        "condition_browse": {
            "mesh_term": [
                "Arthritis", 
                "Arthritis, Rheumatoid"
            ]
        }, 
        "detailed_description": {
            "textblock": "An Open-label, Non-randomized, 2-Period, Fixed Sequence, Single-center Study to Assess the\n      Pharmacokinetics of Rosuvastatin and Simvastatin in Healthy Subjects when Administered Alone\n      and in Combination with Fostamatinib 100 mg Twice Daily."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Provision of signed and dated, written informed consent, prior to any study-specific\n             procedures\n\n          -  Volunteers will be males or females aged 18 to 55 years and with a weight of at least\n             50 kg and body mass index (BMI) between 18 and 30 kg/m2, inclusive.\n\n          -  Male volunteers should be willing to use barrier contraception, ie, condoms, from the\n             day of first dosing until 2 weeks after the last dosing with IP.\n\n          -  Females must have a negative pregnancy test at screening and on admission to the\n             unit, must not be lactating, and must be of non childbearing potential, confirmed at\n             screening .\n\n        Exclusion Criteria:\n\n          -  History of any clinically significant disease or disorder which, in the opinion of\n             the Investigator, may either put the volunteer at risk because of participation in\n             the study, or influence the results or the volunteer's ability to participate in the\n             study.\n\n          -  History or presence of GI, hepatic, or renal disease or any other condition known to\n             interfere with absorption, distribution, metabolism, or excretion of drugs.\n\n          -  Any clinically significant illness, medical/surgical procedure, or trauma within 4\n             weeks of the first administration of IP as judged by the Investigator.\n\n          -  Any clinically significant abnormalities in clinical chemistry, hematology, or\n             urinalysis results as judged by the Investigator.\n\n          -  Any clinically significant abnormal findings in vital signs as judged by the\n             Investigator"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "42", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 7, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01725230", 
            "org_study_id": "D4300C00039"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Rosuvastatin", 
                    "Simvastatin"
                ], 
                "description": "100-mg tablet", 
                "intervention_name": "Fostamatinib", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Rosuvastatin", 
                "description": "20-mg tablet", 
                "intervention_name": "Rosuvastatin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Simvastatin", 
                "description": "40-mg tablet", 
                "intervention_name": "Simvastatin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Simvastatin", 
                "Rosuvastatin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Fostamatinib,", 
            "simvastatin,", 
            "rosuvastatin,", 
            "Phase I,", 
            "Healthy Subjects,", 
            "Pharmacokinetics"
        ], 
        "lastchanged_date": "February 1, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Overland Park", 
                    "country": "United States", 
                    "state": "Kansas"
                }, 
                "name": "Research Site"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "An Open-label, Non-randomized, 2-Period, Fixed Sequence, Single-center Study to Assess the Pharmacokinetics of Rosuvastatin and Simvastatin in Healthy Subjects When Administered Alone and in Combination With Fostamatinib 100 mg Twice Daily", 
        "overall_official": [
            {
                "affiliation": "Quintiles Phase I unit 6700 w 115th st Overland Park, Ks 66211", 
                "last_name": "David Mathews, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "AstraZeneca", 
                "last_name": "Christopher D O'Brien, MD PHD", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "January 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Pharmacokinetics of Rosuvastatin measured by AUC and Cmax.", 
                "safety_issue": "No", 
                "time_frame": "Day 1 and Day 6 at predose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 36 and 48 hours postdose."
            }, 
            {
                "measure": "Pharmacokinetics of Simvastatin measured by AUC and Cmax", 
                "safety_issue": "No", 
                "time_frame": "Day 1 and Day 6 at predose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 36 and 48 hours postdose."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01725230"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Pharmacokinetics of R406 measured by AUC(0-t), Cmax, Tmax (alone and in combination with rosuvastatin or simvastatin)", 
                "safety_issue": "No", 
                "time_frame": "Day 1 to day 4 at predose, Day 5 and Day 6 at predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 hours postdose."
            }, 
            {
                "measure": "Pharmacokinetics of rosuvastatin measured by AUC(0-t), t1/2, Tmax, Cl/F and Vz/F (alone and in combination with fostamatinib)", 
                "safety_issue": "No", 
                "time_frame": "Day 1 and Day 6 at predose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 36 and 48 hours postdose."
            }, 
            {
                "measure": "Pharmacokinetics of Simvastatin measured by AUC(0-t)m t1/2, and Tmax (alone and in combination with fostamatinib)", 
                "safety_issue": "No", 
                "time_frame": "Day 1 and Day 6 at predose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 36 and 48 hours postdose."
            }, 
            {
                "measure": "Pharmacokinetics of simvastatin measured by AUC, Cmax, AUC(0-t), t1/2, Tmax, C1/F and Vz/F (alone and in combination with fostamatinib)", 
                "safety_issue": "No", 
                "time_frame": "Day 1 and Day 6 at predose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 36 and 48 hours postdose."
            }, 
            {
                "measure": "Frequency of adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Measured throughout the study and 3-5 days after discharge from Period 2, approximately 72 days"
            }, 
            {
                "measure": "Severity of adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Measured throughout the study and 3-5 days after discharge from Period 2, approximately 72 days"
            }
        ], 
        "source": "AstraZeneca", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "AstraZeneca", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "January 2013"
    }
}